Clinical Trial of TBK Ointment on Dermatophytosis

The therapeutic effect of antifungal agent, 3-(p-methylbenzylideneamino)-4-phenylthiazoline-2-thione referred as TBK hereafter, was clinically tested on some kinds of tinea. TBK preparations, in a form of carbowax ointment containing one (TBK I) or two (TBK II) percent, was applied. Of 30 subjects tested, there were 19 Tinea cruris, 10 T. interdigitalis and 14 T. pedis. TBK I was applied in 10 subjects and TBK II in 7. In the rest, both preparations were used—different lesions of same individual—for comparison of efficacy according to the concentrations. The therapeutic effects of TBK I and TBK II were 70% and 89% for T. cruris, 71% and 100% for T. interdigitalis, and 17% and 33% for T. pedis, respectively. As to side effects, contact dermatitis was observed only in a patient with T. cruris treated by TBK II.